NIAID DMID Topic 131 (Phase II) "Development of Bacteriophage for Treatment of Mycobacterial Infections"
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health, through NIAID DMID, is forecasting a new requirement for Phase II of Research Topic 131, "Development of Bacteriophage for Treatment of Mycobacterial Infections," with an estimated solicitation release date of September 1, 2026, and an estimated award date of October 1, 2026, both of which precede this forecast's November 14, 2026 posting date. The Total Small Business set-aside under NAICS 541715 funds preclinical research and development of therapeutic phage products that target mycobacteria, with special emphasis on Non-Tuberculous Mycobacterial (NTM) infections and antibiotic-resistant mycobacterial infections. The effort continues a Phase I contract that ended in September 2025, and Phase II activities, described in the attached Statement of Work, include continuation of Phase I activities within a planned, milestone-driven period.
The estimated award value range is $1.5 million to $3 million. Contracting Officer Callie Prassinos (callie.prassinos@nih.gov, +12406695155) is the NIH point of contact, and James Boyce (jim.boyce@nih.gov) is listed as a Department of HHS point of contact.
Forecast text
NIAID DMID Topic 131 (Phase II) "Development of Bacteriophage for Treatment of Mycobacterial Infections"
The goal for Research Topic 131 is to provide support for preclinical research and development of
therapeutic phage products that target mycobacteria. Within this scope, special emphasis is placed on preclinical development of Non-Tuberculous Mycobacterial (NTM) infections; and including antibiotic-resistant mycobacterial infections. This is a continuation of a Phase I contract that ended in September 2025. If not continued in a planned milestone driven Phase II period, the investment in discoveries made during the Phase I period could languish or be lost. Phase II activities are described in the attached Statement of Work and include continuation of Phase I activities.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast